News & meetings
Consortium Meeting, June 2017
The project team met in Rome, Italy, for a first joint progress review meeting.
Start of enrolment – first project clinical study
The First Pacient First Visit (FPFV) milestone was achieved on 9th November 2017. This 2-week EBA study aims to identify a suitable combination of β-lactam antibiotics to treat Tuberculosis.
Consortium Meeting, February 2018
The project team met in Tromso, Norway, for a two-days project meeting. We discussed progress, milestones achieved, implementation difficulties and alternatives moving forward.
End of the first Reporting Period
We reported progress, activities and costs to the EU after the first 18 project months.
Consortium Meeting, February 2019
The project team met in Cape Town, South Africa for a progress review meeting. We also visited the project clinical sites and a hospital in the area.
Start of enrolment – second project clinical study
The First Pacient First Visit (FPFV) milestone was achieved on 27th March 2019. This 2-week EBA study aims to establish proof of concept of anti-TB efficacy in humans of a low-dose oxaborole drug.
Consortium Meeting, July 2019
The project team met in Castelldefels, Spain, coinciding with the Tuberculosis Drug Discovery and Development Gordon Research Conference.
Mid-term review, September 2019
We discussed project progress and plans moving forward with our EU Project Officer.
Grant Agreement amendment
The global TB pipeline is progressing fast and new knowledge and results are being published. The project team reviewed the work plan and requested a GA amendment to maximize the project impact.
End of the second Reporting Period
We reported progress, activities and costs to the EU after 36 months of activity.
Consortium Meeting, May 2020
The project team met by videoconference to discuss project progress and next steps. Our original plan to meet face-to-face in Hamburg was postponed due COVID-19 related mobility restrictions, which are also affecting several project activities.
Consortium Meeting, October 2020
The project team met by videoconference due to COVID-19 related mobility restrictions. The consortium reviewed progress and timelines, including the possibility of requesting a no-cost extension to complete the planned deliverables. The final decision will be made in 2021.
End of enrolment – first project clinical study
The Last Pacient Last Visit (LPLV) milestone was achieved on 4th January 2021. This 2-week EBA study aims to identify a suitable combination of β-lactam antibiotics to treat Tuberculosis. The analysis of data and samples will continue over the following months.
Extension Request, March 2021
The Consortium has requested an extension of six additional months to the project duration. Reason for this is petition is due to the COVID-19 impact on the recruitment in clinical trials and the subsequent delay in the project overall progression towards its remaining deliverables and milestones. The extension will allow to adjust the schedule to the new reality and provide enough additional time to complete the recruitment, and progress towards completion of the project objectives. The project will then change from 60 months duration to 66 months duration, with a new final date on 30/06/2022.
Start of enrolment – third project clinical study
The First Pacient First Visit (FPFV) milestone was achieved on 1st April 2021. This trial will compare therapy outcomes of patients with a biomarker-guided individualized therapy duration vs. standard of care. This approach has the potential to significantly shorten drug-exposure, also reducing adverse events and costs. The identification of patients at risk of therapy failure with need for intensified therapy may also improve patient outcomes and reduce the number of failure cases.
Consortium Meeting, June 2021
The project team met by videoconference due COVID-19 related mobility restrictions. The consortium reviewed progress and fine-tuned the planning to complete deliverables and achieve milestones at (or before) the project end date, now extended to June 2022, after approval of the Grant Agreement amendment request. Being just two weeks ahead of the end of the third reporting period, the partners also reviewed the reporting requirements.